In elderly, untreated patients with AML who are ineligible for standard induction chemotherapy, venetoclax combined with HMA resulted in a CR/CRi rate of 67%, and a CR/CRi of 91.5%, in NPM1-mutated AML (151). This evidence concerns the gene NPM1 and acute myeloid leukemia.